• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Ipsen S.A. ADR (OP: IPSEY )

    28.84 -0.64 (-2.17%)
    Streaming Delayed Price Updated: 3:21 PM EST, Nov 13, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Ipsen S.A. ADR

    < Previous 1 2 Next >
    Week In Review: Foreseen Sells ADC Rights To France's Ipsen In $1 Billion Deal
    In other news, Sichuan Biokin Pharma has filed for an IPO on the Hong Kong Exchange; more on the Biosecure Act being pushed by US Speaker of the House Johnson. 
    Via Talk Markets
    Topics Initial Public Offering
    Exposures Securities Market
    FDA Fast-Tracks Ipsen And Genfit's New Liver Disease Treatment, Iqirvo
    The U.S. FDA has granted accelerated approval for Iqirvo, a novel drug from Ipsen SA and Genfit SA, designed for treating primary biliary cholangitis (PBC). This approval, based on the drug's ability... 
    Via Benzinga
    Exposures Product Safety
    Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing
    Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
    From Virtual Investor Conferences
    Via GlobeNewswire
    Genfit To Buy This Swiss Firm Expanding Its Portfolio in Liver Diseases
    Via Benzinga
    3 Promising Biotech Stocks Flying Under the Radar
    Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks. 
    Via InvestorPlace
    International companies to host live webcasts at Deutsche Bank’s Depositary Receipts
    Virtual Investor Conference on November 8th and 9th, 2023 
    From Virtual Investor Conferences
    Via GlobeNewswire
    Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients
    Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&nbs 
    Via Benzinga
    Genfit's Miss Is CymaBay Therapeutics' Gain: Analyst Says Rival Data Leaves Room for Seladelpar To Emerge As Best-In-Class
    Friday, CymaBay Therapeutics Inc's (NASDAQ: CBAY) competitors Genfit SA (NASDAQ: GNFT) and Ipsen SA (OTC:  
    Via Benzinga
    Ipsen, Genfit's Elafibranor Shows Promise In Primary Biliary Cholangitis Patients
    Ipsen SA (OTC: IPSEY) and Genfit SA (NASDAQ: GNFT)  
    Via Benzinga
    What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur
    On Friday, FDA's Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benefits of Intercept Pharmaceutical Inc's ICPT Ocaliva 25 mg, also known as Obeticholic acid... 
    Via Benzinga
    International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023
    From Virtual Investor Conferences
    Via GlobeNewswire
    Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing
    Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
    From Virtual Investor Conferences
    Via GlobeNewswire
    Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U.
    From Ipsen
    Via Business Wire
    Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde® Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI
    From Ipsen
    Via Business Wire
    International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023
    From Virtual Investor Conferences
    Via GlobeNewswire
    Why These Two Biotech Stocks Blasted Higher This Week
    There's nothing like a big-premium buyout to send a company's share price to the moon. 
    Via The Motley Fool
    2 Tiny Nasdaq Stocks Making Major Merger Moves Monday
    The market is moving higher, and these small companies are helping. 
    Via The Motley Fool
    France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipeline
    Via Benzinga
    Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases
    From Ipsen
    Via Business Wire
    Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva
    From Ipsen
    Via Business Wire
    Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting
    Exelixis Inc (NASDAQ: EXEL) announced that the CONTACT-01 study  
    Via Benzinga
    Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy
    From Ipsen
    Via Business Wire
    Why Merrimack Shares Are Surging Over 200% Today?
    Via Benzinga
    Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
    From Ipsen
    Via Business Wire
    Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
    October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the... 
    Via Benzinga
    Ipsen Delivers Strong Sales Growth in the First Nine Months of 2022 and Confirms Its Full-year Guidance
    From Ipsen
    Via Business Wire
    Ipsen Statement on Updated Timeline for Palovarotene FDA Advisory Committee Meeting
    From Ipsen
    Via Business Wire
    AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
    Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the... 
    Via Benzinga
    Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology
    From Ipsen
    Via Business Wire
    Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022
    From Ipsen
    Via Business Wire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.